Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Sep;71(2-3):397-403.
doi: 10.1016/j.antiviral.2006.05.019. Epub 2006 Jun 19.

Coronaviruses and Their Therapy

Affiliations
Free PMC article
Review

Coronaviruses and Their Therapy

Bart L Haagmans et al. Antiviral Res. .
Free PMC article

Abstract

Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-alpha and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.

Figures

Fig. 1
Fig. 1
Phylogenetic tree based on deduced amino acid sequences of the coronavirus replicase ORF1b gene for bovine coronavirus (BCoV), human coronavirus 22E (HuCoV-OC43), mouse hepatitis virus (MHV), SARS-CoV, infectious bronchitis virus (IBV), transmissible gastroenteritis virus (TGEV), feline infectious peritonitis virus (FIPV), porcine epidemic diarrhea virus (PEDV), human coronavirus 229E (HuCoV-229E), human coronavirus NL63 (HuCoV-NL63) and Berne Torovirus (used as an outgroup).
Fig. 2
Fig. 2
Schematic overview of the SARS-CoV lifecycle and inhibitors of viral replication.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

References

    1. Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. - PubMed
    1. Balzarini J. Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis. 2005;5(11):726–731. - PubMed
    1. Balzarini J., Keyaerts E., Vijgen L., Vandermeer F., Stevens M., De Clercq E., Egberink H.J., Van Ranst M. Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture. J. Ant. Chemother. 2006;57:472–481. - PMC - PubMed
    1. Barnard D.L., Hubbard V.D., Burton J., Smee D.F., Morrey J.D., Otto M.J., Sidwell R.W. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-d-N4-hydroxycytidine. Antiviral Chem. Chemother. 2004;15:15–22. - PubMed
    1. Barnard D.L., Day C.W., Bailey K., Heiner M., Montgomery R., Lauridsen L., Winslow S., Hoopes J., Li J.K., Lee J., Carson D.A., Cottam H.B., Sidwell R.W. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res. 2006 (Epub) - PMC - PubMed

MeSH terms

Feedback